Our findings have confirmed that resistance to these agents is likely across a variety of malignancies and that point mutations in Aurora B, particularly of the 160 residue, may be highly significant markers of treatment outcome.
← all excerpts
Evolution of resistance to Aurora kinase B inhibitors in leukaemia cells.
1
—
—